Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Non-Current Liabilities (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 42.73% to $13.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Dec 2025, up 42.73% year-over-year, with the annual reading at $13.8 million for FY2025, 42.73% up from the prior year.
  • Total Non-Current Liabilities hit $13.8 million in Q4 2025 for Insight Molecular Diagnostics, up from $9.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $81.9 million in Q1 2022 to a low of $8.5 million in Q2 2025.
  • Historically, Total Non-Current Liabilities has averaged $30.6 million across 5 years, with a median of $25.2 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 464.85% in 2022 and later tumbled 84.27% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $24.7 million in 2021, then skyrocketed by 122.96% to $55.1 million in 2022, then dropped by 14.27% to $47.3 million in 2023, then crashed by 79.59% to $9.6 million in 2024, then surged by 42.73% to $13.8 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for IMDX at $13.8 million in Q4 2025, $9.2 million in Q3 2025, and $8.5 million in Q2 2025.